Ionis Pharmaceuticals (IONS) and its majority-owned spinoff Akcea Therapeutics (AKCA) work together on RNA-based therapies for a wide spectrum of diseases. On January 22, 2020, they announced that the potential therapy AKCEA-APOCIII-LRx for hypertriglyceridemia (high triglycerides in the blood) displayed positive Phase 2 results. While a confirmatory Phase 3 trial will be necessary to obtain commercial approval, if all goes well this could start boosting revenue in 2022 or 2023.
Akcea was spun off from Ionis, which now owns about 75% of it. Because Ionis shareholders in effect own Akcea, but